What drives $BMY M&amp;A strategy today? It’s called Keytruda envy — $MRK Keytruda at $13B sales and growing vs $BMY Opdivo sales at $7B and alarmingly flat. Desperately seeking checkpoint inhibitor synergy with PD-1 Opdivo.  Needs $TRIL CD47 and $CGEN TIGIT - PVRIG https://t.co/tA3UoxFOGx